Cost-effectiveness analysis of HPV vaccination of men who have sex with men in Germany.

ABSTRACT:

Introduction

Men who have sex with men (MSM) have a high risk of human papillomavirus (HPV) infection and HPV-related diseases. While gender neutral HPV vaccination between the ages of 9-14 years (with the option for catch-up between 15- and 17-years-of-age) has been recommended in Germany since 2018, adult MSM are currently not included and thus do not benefit from its advantages. This analysis aims to quantify the reduction in public health and health economic burden of including 18-26-year-old or 18-45-year-old MSM in the national HPV vaccination recommendation, compared to the status quo of vaccinating adolescent boys only.

Methods

We developed a dynamic transmission model of HPV, with an integrated HIV model, to analyze the potential impact of the 9-valent HPV vaccinati

SUBMITTER: Palmer C 

PROVIDER: S-EPMC12675683 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature